This cannabinoid bioavailability review looks at a 2025 crossover study testing a nanoemulsified THC/CBD powder against standard oil drops in healthy volunteers. The study found faster absorption and higher cannabinoid exposure with the powder formulation. But cannabinoid bioavailability is not the same as proven clinical benefit, and that distinction matters for patients, providers, and policymakers.